ATE406797T1 - Exo-s-mecamylamin-formulierung - Google Patents
Exo-s-mecamylamin-formulierungInfo
- Publication number
- ATE406797T1 ATE406797T1 AT05024899T AT05024899T ATE406797T1 AT E406797 T1 ATE406797 T1 AT E406797T1 AT 05024899 T AT05024899 T AT 05024899T AT 05024899 T AT05024899 T AT 05024899T AT E406797 T1 ATE406797 T1 AT E406797T1
- Authority
- AT
- Austria
- Prior art keywords
- exo
- mecamylamine
- pharmaceutically acceptable
- disorder
- amount
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11253498P | 1998-12-16 | 1998-12-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE406797T1 true ATE406797T1 (de) | 2008-09-15 |
Family
ID=22344414
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT05024899T ATE406797T1 (de) | 1998-12-16 | 1999-12-16 | Exo-s-mecamylamin-formulierung |
AT99967401T ATE320711T1 (de) | 1998-12-16 | 1999-12-16 | Exo-s-mecamylamin-formulierung und ihre verwendung in behandlungen |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT99967401T ATE320711T1 (de) | 1998-12-16 | 1999-12-16 | Exo-s-mecamylamin-formulierung und ihre verwendung in behandlungen |
Country Status (12)
Country | Link |
---|---|
US (1) | US20020016370A1 (de) |
EP (3) | EP1139744A4 (de) |
JP (5) | JP2002532392A (de) |
AT (2) | ATE406797T1 (de) |
AU (2) | AU2368600A (de) |
CA (2) | CA2393437C (de) |
CY (1) | CY1108577T1 (de) |
DE (2) | DE69939498D1 (de) |
DK (2) | DK1634498T3 (de) |
ES (2) | ES2260959T3 (de) |
PT (2) | PT1139743E (de) |
WO (2) | WO2000035280A1 (de) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE521512C2 (sv) | 2001-06-25 | 2003-11-11 | Niconovum Ab | Anordning för administrering av en substans till främre delen av en individs munhåla |
US7045534B2 (en) | 2002-02-12 | 2006-05-16 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of reducing angiogenesis |
WO2004056363A2 (en) | 2002-12-20 | 2004-07-08 | Niconovum Ab | A physically and chemically stable nicotine-containing particulate material |
US20070224284A1 (en) | 2004-03-12 | 2007-09-27 | John Devane | Methods and compositions comprising at least one alpha3 beta4 nAChR antagonist or pharmaceutically acceptable salt thereof |
MXPA05009640A (es) * | 2003-03-14 | 2005-10-26 | Agi Therapeutics Ltd | Tratamiento de condiciones intestinales con n-2,3,3-tetrametilbiciclo [2.2.1] heptan-3-amina. |
DE10318714B4 (de) * | 2003-04-25 | 2006-03-23 | Hf Arzneimittelforschung Gmbh | Wirkstoff-Kombinationen und Therapien zur Bekämpfung des Alkoholmissbrauches |
JP5254616B2 (ja) | 2004-09-13 | 2013-08-07 | クロノ セラピューティクス、インコーポレイテッド | 生物学的同調性(biosynchronous)経皮的薬物送達 |
US8252321B2 (en) | 2004-09-13 | 2012-08-28 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
KR20080081175A (ko) * | 2005-12-19 | 2008-09-08 | 코멘티스, 인코포레이티드 | 안구 투여를 위한 국소 메카밀라민 제형 및 그것의 사용 |
CA2646942C (en) | 2006-03-16 | 2014-07-29 | Niconovum Ab | Improved snuff composition |
MX2009003845A (es) * | 2006-10-09 | 2009-04-23 | Smithkline Beecham Corp | Composiciones para reducir los sintomas de abstinencia de nicotina y/o el uso del tabaco. |
US20080243005A1 (en) * | 2007-03-30 | 2008-10-02 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational user-health testing |
US20090119154A1 (en) * | 2007-11-07 | 2009-05-07 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Determining a demographic characteristic based on computational user-health testing of a user interaction with advertiser-specified content |
US20080242948A1 (en) * | 2007-03-30 | 2008-10-02 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Effective low-profile health monitoring or the like |
US20080319276A1 (en) * | 2007-03-30 | 2008-12-25 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational user-health testing |
US20080242947A1 (en) * | 2007-03-30 | 2008-10-02 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Configuring software for effective health monitoring or the like |
US20080242949A1 (en) * | 2007-03-30 | 2008-10-02 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational user-health testing |
US20080242951A1 (en) * | 2007-03-30 | 2008-10-02 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Effective low-profile health monitoring or the like |
US20080242952A1 (en) * | 2007-03-30 | 2008-10-02 | Searete Llc, A Limited Liablity Corporation Of The State Of Delaware | Effective response protocols for health monitoring or the like |
US20090005654A1 (en) * | 2007-03-30 | 2009-01-01 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational user-health testing |
US20090018407A1 (en) * | 2007-03-30 | 2009-01-15 | Searete Llc, A Limited Corporation Of The State Of Delaware | Computational user-health testing |
US20090005653A1 (en) * | 2007-03-30 | 2009-01-01 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational user-health testing |
EP2322166A1 (de) * | 2007-04-02 | 2011-05-18 | Parkinson's Institute | Verfahren und Zusammensetzung zur Verringerung der Nebenwirkungen von therapeutischen Behandlungen |
US8569381B2 (en) | 2008-05-23 | 2013-10-29 | Targacept, Inc. | Combination therapy for the management of hypertension |
AT507187B1 (de) * | 2008-10-23 | 2010-03-15 | Helmut Dr Buchberger | Inhalator |
KR20120048611A (ko) * | 2009-07-14 | 2012-05-15 | 타가셉트 인코포레이티드 | 치료를 위한 엑소-s-메카밀아민 방법, 용도, 및 화합물 |
JO3250B1 (ar) | 2009-09-22 | 2018-09-16 | Novartis Ag | إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7 |
AU2011258553B2 (en) * | 2010-05-27 | 2014-08-14 | Targacept, Inc. | Nicotinic receptor non-competitive antagonists |
CN103491815B (zh) | 2011-02-11 | 2016-01-20 | 巴特马克有限公司 | 吸入器组件 |
AT510837B1 (de) | 2011-07-27 | 2012-07-15 | Helmut Dr Buchberger | Inhalatorkomponente |
US20130017259A1 (en) | 2011-07-06 | 2013-01-17 | The Parkinson's Institute | Compositions and Methods for Treatment of Symptoms in Parkinson's Disease Patients |
EP3892125A3 (de) | 2011-09-06 | 2022-01-05 | Nicoventures Trading Limited | Erwärmung eines rauchmaterials |
BR112013032558B1 (pt) | 2011-09-06 | 2021-01-12 | British American Tobacco (Investments) Limited | aparelho para aquecer material fumável |
AT511344B1 (de) | 2011-10-21 | 2012-11-15 | Helmut Dr Buchberger | Inhalatorkomponente |
US8901177B2 (en) * | 2012-03-23 | 2014-12-02 | Targacept, Inc. | Method of treating bladder disorders |
GB201207039D0 (en) | 2012-04-23 | 2012-06-06 | British American Tobacco Co | Heating smokeable material |
GB2504076A (en) | 2012-07-16 | 2014-01-22 | Nicoventures Holdings Ltd | Electronic smoking device |
GB2513639A (en) | 2013-05-02 | 2014-11-05 | Nicoventures Holdings Ltd | Electronic cigarette |
GB2513637A (en) | 2013-05-02 | 2014-11-05 | Nicoventures Holdings Ltd | Electronic cigarette |
GB2514893B (en) | 2013-06-04 | 2017-12-06 | Nicoventures Holdings Ltd | Container |
GB201407426D0 (en) | 2014-04-28 | 2014-06-11 | Batmark Ltd | Aerosol forming component |
GB2528673B (en) | 2014-07-25 | 2020-07-01 | Nicoventures Holdings Ltd | Aerosol provision system |
CN106999449B (zh) | 2014-08-22 | 2021-04-02 | 阿塔卡马治疗股份有限公司 | 用于治疗多汗症的方法 |
GB2533135B (en) | 2014-12-11 | 2020-11-11 | Nicoventures Holdings Ltd | Aerosol provision systems |
CA2974324A1 (en) | 2015-01-28 | 2016-08-04 | Zita S. Netzel | Drug delivery methods and systems |
WO2016145373A1 (en) | 2015-03-12 | 2016-09-15 | Chrono Therapeutics Inc. | Craving input and support system |
GB201511349D0 (en) | 2015-06-29 | 2015-08-12 | Nicoventures Holdings Ltd | Electronic aerosol provision systems |
US20170055584A1 (en) | 2015-08-31 | 2017-03-02 | British American Tobacco (Investments) Limited | Article for use with apparatus for heating smokable material |
US11924930B2 (en) | 2015-08-31 | 2024-03-05 | Nicoventures Trading Limited | Article for use with apparatus for heating smokable material |
AU2017256084B2 (en) | 2016-04-27 | 2020-09-24 | Nicoventures Trading Limited | Electronic aerosol provision system and vaporizer therefor |
AU2018205529B2 (en) | 2017-01-06 | 2023-08-10 | Morningside Venture Investments Limited | Transdermal drug delivery devices and methods |
JP7420797B2 (ja) | 2018-05-29 | 2024-01-23 | モーニングサイド ベンチャー インベストメンツ リミテッド | 薬剤送達の方法及びシステム |
GB202203728D0 (en) * | 2022-03-17 | 2022-05-04 | Univ Oxford Innovation Ltd | Treatments and methods for increasing dopamine |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5039801A (en) * | 1985-12-20 | 1991-08-13 | The United States Of America As Represented By The Department Of Health & Human Services | Thermal fragmentation of methylbenzylurea disastereomers or secondary amines and preparation of optically active secondary amines |
US4749686A (en) * | 1986-12-04 | 1988-06-07 | New York Medical College | Combinations of renal vasodilators and α1 -adrenergic or ganglionic blocking agents and methods for treating diseases |
EP0302595B1 (de) * | 1987-07-07 | 1994-02-02 | Beecham Group Plc | Pinacidil zur Behandlung von pulmonaler Hypertonie oder Rechtsversagen |
US5691365A (en) * | 1995-07-18 | 1997-11-25 | University Of Kentucky Research Foundation | Nicotinic receptor antagonists in the treatment of neuropharmacological disorders |
-
1999
- 1999-12-16 PT PT99967401T patent/PT1139743E/pt unknown
- 1999-12-16 DK DK05024899T patent/DK1634498T3/da active
- 1999-12-16 EP EP99967396A patent/EP1139744A4/de not_active Withdrawn
- 1999-12-16 CA CA002393437A patent/CA2393437C/en not_active Expired - Fee Related
- 1999-12-16 PT PT05024899T patent/PT1634498E/pt unknown
- 1999-12-16 AU AU23686/00A patent/AU2368600A/en not_active Abandoned
- 1999-12-16 AU AU23682/00A patent/AU2368200A/en not_active Abandoned
- 1999-12-16 EP EP05024899A patent/EP1634498B1/de not_active Expired - Lifetime
- 1999-12-16 ES ES99967401T patent/ES2260959T3/es not_active Expired - Lifetime
- 1999-12-16 WO PCT/US1999/030137 patent/WO2000035280A1/en not_active Application Discontinuation
- 1999-12-16 WO PCT/US1999/030153 patent/WO2000035279A1/en active IP Right Grant
- 1999-12-16 AT AT05024899T patent/ATE406797T1/de active
- 1999-12-16 CA CA002393442A patent/CA2393442A1/en not_active Abandoned
- 1999-12-16 EP EP99967401A patent/EP1139743B1/de not_active Expired - Lifetime
- 1999-12-16 ES ES05024899T patent/ES2313187T3/es not_active Expired - Lifetime
- 1999-12-16 DE DE69939498T patent/DE69939498D1/de not_active Expired - Lifetime
- 1999-12-16 DK DK99967401T patent/DK1139743T3/da active
- 1999-12-16 AT AT99967401T patent/ATE320711T1/de active
- 1999-12-16 JP JP2000587608A patent/JP2002532392A/ja active Pending
- 1999-12-16 DE DE69930552T patent/DE69930552T2/de not_active Expired - Lifetime
- 1999-12-16 JP JP2000587609A patent/JP2002532393A/ja not_active Withdrawn
-
2001
- 2001-06-15 US US09/882,934 patent/US20020016370A1/en not_active Abandoned
-
2008
- 2008-11-19 CY CY20081101333T patent/CY1108577T1/el unknown
-
2011
- 2011-03-14 JP JP2011055716A patent/JP2011126909A/ja not_active Withdrawn
-
2013
- 2013-12-13 JP JP2013258032A patent/JP2014051528A/ja active Pending
-
2016
- 2016-01-25 JP JP2016011658A patent/JP2016065108A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
PT1634498E (pt) | 2008-10-28 |
DE69930552T2 (de) | 2006-11-30 |
JP2014051528A (ja) | 2014-03-20 |
DK1634498T3 (da) | 2008-12-15 |
PT1139743E (pt) | 2006-06-30 |
ATE320711T1 (de) | 2006-04-15 |
EP1139743A4 (de) | 2003-01-02 |
ES2260959T3 (es) | 2006-11-01 |
JP2002532393A (ja) | 2002-10-02 |
CA2393437A1 (en) | 2000-06-22 |
EP1139743A1 (de) | 2001-10-10 |
AU2368200A (en) | 2000-07-03 |
ES2313187T3 (es) | 2009-03-01 |
CY1108577T1 (el) | 2014-04-09 |
DE69939498D1 (de) | 2008-10-16 |
AU2368600A (en) | 2000-07-03 |
EP1634498A3 (de) | 2006-03-29 |
EP1139743B1 (de) | 2006-03-22 |
EP1634498B1 (de) | 2008-09-03 |
JP2002532392A (ja) | 2002-10-02 |
WO2000035279A1 (en) | 2000-06-22 |
DE69930552D1 (de) | 2006-05-11 |
EP1634498A2 (de) | 2006-03-15 |
DK1139743T3 (da) | 2006-07-31 |
JP2011126909A (ja) | 2011-06-30 |
CA2393437C (en) | 2009-12-15 |
CA2393442A1 (en) | 2000-06-22 |
EP1139744A1 (de) | 2001-10-10 |
EP1139744A4 (de) | 2003-01-02 |
US20020016370A1 (en) | 2002-02-07 |
JP2016065108A (ja) | 2016-04-28 |
WO2000035280A1 (en) | 2000-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1634498T3 (da) | Exo-S-mecamylamine formulation | |
PT740650E (pt) | Co-farmacos como um metodo de administracao controlada de farmacos | |
BR0206559A (pt) | Uso de um composto, método de tratamento ou prevenção de disfunções, uso ou método, método de neuroproteção e composto | |
ATE253039T1 (de) | Beta 2 -adrenergische rezeptor-agonisten | |
JP2002532392A5 (de) | ||
BRPI0506881A (pt) | derivado de arila diazabicìclica, composição farmacêutica, uso de um derivado de arila diazabicìclica, e, método de tratamento, prevenção ou alìvio de uma doença ou distúrbio ou condição de um corpo de animal vivo | |
Summers et al. | THA—a review of the literature and its use in treatment of five overdose patients | |
NZ522326A (en) | Adenosine A2A receptor antagonists | |
MX348062B (es) | Mutantes que degradan proteoglicanos para tratamiento del snc. | |
RU93043625A (ru) | Композиция, включающая вещество трамадол и ацетаминофен, и способ лечения с ее использованием | |
ATE433959T1 (de) | Analoge von kokain | |
HK1044333A1 (zh) | 趨化因子受體拮抗劑及其使用方法 | |
DK1212060T3 (da) | Anvendelse af nikotin eller derivater heraf samt L-DOPA i et lægemiddel til behandling af neurologiske sygdomme, især Parkinsons sygdom | |
Sun et al. | Management of tetanus: a review of 18 cases | |
NO317485B1 (no) | Fremgangsmate for fremstilling av ZME-018 gelonin immunokonjugat for behandling av melanom | |
JP2003516947A (ja) | ニコチン様物質受容体のモジュレーターとしてのガランタミンおよびリコラミンの類似物 | |
WO2001081328A3 (en) | Thiazolidinedione analogues and their use for the treatment of diabetes | |
Durant et al. | Comparison of the neuromuscular blocking properties of Org NC 45 and pancuronium in the rat, cat and rhesus monkey | |
IS4847A (is) | Aðferð til meðferðar gegn hjartabilun þar sem notuð eru mótlyf gegn endóþelíni | |
IL80476A0 (en) | Prazosin-pirbuterol combination for bronchodilation | |
KR970701545A (ko) | 퀴놀린-3-카르복사미드 화합물의 새로운 용도(new use of quinoline-3-carboxamide compounds) | |
Mison-Crighel et al. | Glutaminase activity and neocortical excitability | |
Booij | The history of neuromuscular blocking agents | |
Messer et al. | Synthesis, biochemical activity and behavioral effects of a series of 1, 4, 5, 6-tetrahydropyrimidines as novel ligands for M1 receptors | |
Ajit et al. | Illicit Drugs and their Assessment: A Brief Review |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1634498 Country of ref document: EP |